Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection after a single dose TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses CHATHAM, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company with marketed products and a pipeline ...

Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion TNX-1700 (hTFF2-HSA fusion protein) is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharm ...

CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the open of U.S. equity markets today, June 30, 2025, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as ...

Core Insights - Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is currently viewed as a promising investment opportunity based on recent observations [1] Company Overview - The company has been under close observation for a significant period, indicating a potential shift in market dynamics that could favor its stock performance [1] Market Context - The investment landscape has been influenced by various historical events, including the dot com bubble, the credit default crisis of 2008, and the recent AI boom, suggesting that the company operates in a volatile yet potentially lucrative environment [1]

Group 1 - Tonix Pharmaceuticals is a clinical-stage biotechnology firm focused on developing TNX-102 SL, a compound aimed at improving sleep quality in fibromyalgia patients [1] - The FDA is currently reviewing TNX-102 SL, with a Prescription Drug User Fee Act (PDUFA) date set for August 15, 2025 [1] - The company aims to bridge the gap between scientific advancements and financial strategies in the healthcare sector, assisting clients in uncovering hidden value and assessing risks [1]

Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year CHATHAM, N.J., June 13 ...

Group 1 - U.S. stock futures are lower, with Dow futures dropping over 250 points [1] - Oxford Industries reported adjusted EPS of $1.82, meeting estimates, and quarterly sales of $392.86 million, exceeding expectations of $384.77 million [2] - Oxford Industries shares fell 10.1% to $44.99 in pre-market trading after issuing second-quarter earnings guidance below estimates and lowering FY25 guidance [2] Group 2 - Tonix Pharmaceuticals Holding Corp. shares dipped 17% to $31.32 as the company may sell up to $150 million in common stock [5] - GameStop Corp. shares fell 12.4% to $24.97 following the announcement of a $1.75 billion proposed private offering of convertible senior notes [5] - The Boeing Company shares decreased 7.4% to $198.10 after an Air India Boeing 787-8 Dreamliner crashed near Ahmedabad airport [5]

* Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (To ...

A copy of the Company's poster presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the EULAR website here. CHATHAM, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced a poster presentation at ...

CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals participated in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase. A webcast of the presentation can be found under the IR Events tab of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals H ...